Stocklytics Platform
Alzamend Neuro
ALZN46
$1.02arrow_drop_down1.92%-$0.02
NASDAQ - As of Apr 4, 5:49 PM EDT Market Closed
Penny Stock
ALZN46

$1.02

arrow_drop_down1.92%

Performance History

no data available for performance history chart

There's no data available for performance history chart

no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Stocklytics logo

Period: Next 12 Months

Predicted: just now

info

Analyzed by 2 Wall Street experts, Alzamend Neuro's 12-month projections average at $4.75, spanning from a high of $8.00 to a low of $1.50. This signifies an 383.36% shift from the current price of $1.02.

Analyst Ratings

Buy / Hold

Buy
1
50.00%
Hold
1
50.00%
Sell
0
0.00%
Ratings from: April

Last updated: just now

Total: 2
info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

Price$788.17
Perf. (24h)arrow_drop_down0.11%-$0.91
Market Cap$708.73B
Price$538.05
Perf. (24h)arrow_drop_down0.45%-$2.44
Market Cap$494.34B
Price$159.39
Perf. (24h)arrow_drop_down0.39%-$0.62
Market Cap$397.30B
Price$199.86
Perf. (24h)arrow_drop_down0.88%-$1.77
Market Cap$356.69B

About Alzamend Neuro (ALZN)

Alzamend Neuro, Inc. (ALZN) is a biopharmaceutical company focused on developing innovative therapies for the treatment of Alzheimer's disease. With a mission to improve the lives of those affected by this devastating neurodegenerative disease, ALZN is dedicated to finding solutions to one of the greatest healthcare challenges of our time. The company's primary focus is on developing novel therapeutic drug candidates that target the underlying mechanisms of Alzheimer's disease, with the ultimate goal of slowing or halting disease progression. ALZN's research and development efforts are backed by a team of leading experts in the field of neurology and Alzheimer's disease.
As of the latest available information, the stock price of Alzamend Neuro, Inc. (ALZN) is not provided. It is recommended to check reliable financial sources for the most up-to-date stock price. ALZN is a publicly traded company, and its stock price can be influenced by various factors, including market conditions, company performance, and investor sentiment.
Show more
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephan Jackman
Headquarters
Atlanta
Employees
4
Exchange
NASDAQ
add Alzamend Neuro to watchlist

Keep an eye on Alzamend Neuro

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Alzamend Neuro's (ALZN) price per share?

The current price per share for Alzamend Neuro (ALZN) is $1.02. The stock has seen a price change of -$0.02 recently, indicating a -1.92% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Alzamend Neuro (ALZN)?

For Alzamend Neuro (ALZN), the 52-week high is $33.75, which is 3.21K% from the current price. The 52-week low is $0.65, the current price is 57.89% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Alzamend Neuro (ALZN) a growth stock?

Alzamend Neuro (ALZN) has shown an average price growth of -1.65% over the past three years. It has received a score of 49 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alzamend Neuro as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Alzamend Neuro (ALZN) stock price performance year to date (YTD)?

As of the latest data, Alzamend Neuro (ALZN) has a year-to-date price change of -12.07%. Over the past month, the stock has experienced a price change of 34.99%. Over the last three months, the change has been -19.05%. Over the past six months, the figure is -37.42%.
help

Is Alzamend Neuro (ALZN) a profitable company?

Alzamend Neuro (ALZN) has a net income of -$9.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$9.94M. Furthermore, the EBITDA is -$5.78M.
help

What is the market capitalization of Alzamend Neuro (ALZN)?

Alzamend Neuro (ALZN) has a market capitalization of $6.73M. The average daily trading volume is 1, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level